证券代码：002100 证券简称：天康生物 天康生物股份有限公司 投资者关系活动记录表 编号：2016-005 | --- | --- | --- | |-----------------------|--------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 东兴证券杨钊；华夏基金刘文成。 | | | 人员姓名 | | | | 时间 | 2016 年 10 月 28 | 日 | | 地点 | 新疆乌鲁木齐市高新区长春南路 | 528 号天康企业大厦 11 楼 | | | 3 号会议室 | | | 上市公司接待人 员姓名 | 董事会秘书郭运江 | | | 投资者关系活动 | 1 、公司养殖板块情况 | | ...

证券代码：002100 证券简称：天康生物 天康生物股份有限公司 投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |-----------------------|-------------------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 申万宏源证券宫衍海、太平洋证券梁艳 | | 人员姓名 | | | | 时间 | 2017 年 5 月 5 日 | | | 地点 | 新疆乌鲁木齐市高新区长春南路 3 号会议室 | 528 号天康企业大厦 11 楼 | | 上市公司接待人 员姓名 | 董事会秘书郭运江 | | | 投资者关系活动 | 公司 2016 | 年营业收入 ...

证券代码：002100 证券简称：天康生物 天康生物股份有限公司 投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |-------------------------|-------------------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 兴业证券毛一凡、王亦奕；华山西太钢投资公司刘俊。 | | 时间 | 2017 年 2 月 15 日 | | | | | | | 地点 | 新疆乌鲁木齐市高新区长春南路 3 号会议室 | 528 号天康企业大厦 11 楼 | | 上市公司接待人 员姓名 | 董事会秘书郭运江 | | | 投资者关系活动 | 一、公司疫苗板 ...

证券代码：002100 证券简称：天康生物 天康生物股份有限公司 投资者关系活动记录表 编号：2017-002 | --- | --- | --- | |-----------------------|----------------------------------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中信证券彭家乐 | | | 人员姓名 | | | | | | | | 时间 地点 | 2017 年 3 月 9 日 新疆乌鲁木齐市高新区长春南路 | 528 号天康企业大厦 11 楼 | | | 3 号会议室 | | | 上市公司接待人 员姓名 | 董事会秘书郭运江 | | | 投资者关系活动 | 公司 ...

证券代码：002100 证券简称：天康生物 天康生物股份有限公司 投资者关系活动记录表 编号：2017-004 | --- | --- | --- | |----------------|--------------------------------|--------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 华融证券刘德威、方正证券张千叶 | | | 人员姓名 | | | | 时间 | 2017 年 8 月 24 日 | | | 地点 | 新疆乌鲁木齐市高新区长春南路 | 528 号天康企业大厦 11 楼 | | | 董事会秘书办公室 | | | 上市公司接待人 | 董事会秘书郭运江 | | | 员姓名 | | | 1 | --- | --- | |------------------------|-------- ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥4,876,888,188.45, representing a 10.53% increase year-over-year[6]. - Net profit attributable to shareholders for Q3 2022 reached ¥355,439,234.76, a significant increase of 181.85% compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥362,232,096.57, up 183.93% year-over-year[6]. - Basic earnings per share for Q3 2022 were ¥0.26, reflecting a 165.00% increase from ¥0.19 in the same quarter last year[6]. - The company's net profit attributable to shareholders rose to ¥2.48 billion, compared to ¥2.22 billion in the previous year, an increase of approximately 11.7%[27]. - Basic earnings per share for the current period is 0.19, compared to -0.18 in the previous period[33]. - The total comprehensive income attributable to shareholders of the parent company is 245,186,269.12, while the previous period showed a loss of 158,326,403.58[33]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥18,963,552,324.99, marking a 10.35% increase from the end of the previous year[6]. - Total assets increased to ¥18.96 billion as of September 30, 2022, compared to ¥17.18 billion at the beginning of the year, reflecting a growth of approximately 10.4%[27]. - The total liabilities decreased to ¥9.31 billion from ¥9.40 billion, a decline of approximately 0.9%[27]. - The equity attributable to shareholders increased to ¥7.89 billion from ¥7.15 billion, reflecting a growth of about 10.3%[27]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,833,785,122.11, down 49.47% compared to the same period last year[13]. - The net cash flow from operating activities decreased to 1,833,785,122.11 from 3,629,302,404.17 in the previous period[37]. - The net cash flow from financing activities was ¥1,443,593,555.22, a 192.00% increase, primarily due to increased investments from shareholders[13]. - The net cash flow from financing activities is 1,443,593,555.22, a significant improvement from -1,569,136,550.80 in the previous period[40]. - The total cash and cash equivalents at the end of the period is 5,811,695,832.70, up from 2,767,644,090.16 in the previous period[40]. Investments and Shareholding - The company reported a total of 283,929,184 shares held by its largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd., representing a significant portion of ownership[17]. - Xinjiang Tianbang Hongkang Venture Capital Partnership holds 62,580,733 shares, accounting for 4.62% of the total shares[17]. - The company has initiated a mixed-ownership reform plan for Tiankang Pharmaceutical (Suzhou) Co., Ltd., approved by the board on June 1, 2022, to attract external strategic investors and employee shareholding[20]. - The share price for the external strategic investment in Tiankang Pharmaceutical was set at 15.81 yuan per unit of registered capital during the public solicitation process[21]. - As of September 25, 2022, all new shareholders of Tiankang Pharmaceutical have completed their capital contributions[21]. - The company is actively expanding its market presence through strategic partnerships and investments in Tiankang Pharmaceutical[20]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder having no related party relationships with others[17]. - The company is focused on enhancing its capital structure through the introduction of new investors and employee ownership initiatives[20]. Research and Development - Research and development expenses increased by 72.71% to ¥50,492,134.33, indicating a focus on innovation[13]. - Research and development expenses for the quarter were ¥122.35 million, up from ¥103.20 million, indicating an increase of about 18.5%[30]. Other Financial Metrics - The company's cash and cash equivalents increased to ¥5.92 billion from ¥3.42 billion, marking a significant growth of about 73.1%[24]. - Inventory decreased to ¥3.93 billion from ¥5.23 billion, a reduction of approximately 24.8%[24]. - Long-term borrowings increased to ¥2.89 billion from ¥1.96 billion, reflecting a growth of about 47.3%[27]. - The company's long-term borrowings rose by 47.06% to ¥2,888,269,363.22, reflecting adjustments in loan structure[13]. - The total profit for the current period is 217,953,683.97, compared to a loss of 57,757,472.82 in the previous period[33]. - The net profit attributable to shareholders of the parent company is 257,958,881.22, while the previous period showed a loss of 192,859,153.56[33]. - The net cash flow from investing activities is -777,460,915.19, compared to -1,242,949,423.18 in the previous period[40]. - The company reported a decrease in other comprehensive income, with a net amount of -12,772,612.10 compared to 34,532,749.98 in the previous period[33].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥8,008,625,554.64, representing a 1.16% increase compared to ¥7,916,638,583.45 in the same period last year[27]. - The net profit attributable to shareholders of the listed company was -¥97,480,353.54, a decrease of 140.38% from ¥241,396,816.85 in the previous year[27]. - The net cash flow from operating activities was ¥389,762,424.56, down 86.59% from ¥2,907,019,096.74 in the same period last year[27]. - The basic earnings per share were -¥0.07, a decline of 131.82% compared to ¥0.22 in the previous year[27]. - Total assets at the end of the reporting period were ¥16,228,737,642.33, a decrease of 5.56% from ¥17,184,738,668.37 at the end of the previous year[27]. - The net assets attributable to shareholders of the listed company were ¥7,026,317,148.09, down 1.71% from ¥7,148,418,633.08 at the end of the previous year[27]. Operational Challenges - The company reported a significant decrease in net profit due to various operational challenges faced during the reporting period[27]. - The company faced challenges in achieving expected benefits due to low pork prices influenced by domestic market conditions[73]. - The company has faced challenges in project profitability due to the impact of African swine fever and fluctuating market conditions[92]. Strategic Focus - The company is focusing on improving its operational efficiency and exploring new market opportunities to enhance future performance[27]. - The management has outlined strategies to mitigate risks and adapt to market changes in the upcoming periods[27]. - The company plans to gradually expand the "company + farmers" breeding model as its pig farming scale increases[48]. - The company has identified opportunities for large-scale breeding enterprises to expand their scale due to the exit of many small and medium-sized farmers from the market[92]. Revenue Breakdown - The company sold 109.74 million tons of feed, a year-on-year decrease of 2.90%, with sales revenue of 275,183.27 million yuan, an increase of 6.35%[45]. - The company reported a sales revenue of 220,380.27 million yuan from pig farming, a year-on-year increase of 29.75%, with 931,500 pigs sold, a year-on-year increase of 26.53%[47]. - The company's plant protein and oil processing business generated sales revenue of 102,484.06 million yuan, a year-on-year increase of 17.83%[47]. - The company's corn storage business saw a sales revenue of 128,633.18 million yuan, a year-on-year decrease of 38.68%[47]. - The overall gross margin for the company's main business was 6.82%, a decrease of 9.09 percentage points year-on-year[47]. Investment and Assets - The company invested over ¥200 million in the construction of a high-level biosafety laboratory (P3), which was completed and put into use in 2020[51]. - The company achieved a net cash flow from operating activities of ¥389,762,424.56, a decrease of 86.59% compared to ¥2,907,019,096.74 in the previous year[55]. - The company reported a significant increase in fixed assets, which rose to 4.899 billion, accounting for 30.19% of total assets[63]. - The company has invested a total of 98,550 million CNY through convertible bonds, with 1,606.32 million CNY utilized in the current period and a cumulative usage of 81,253.92 million CNY[84]. Environmental Compliance - The company reported a total wastewater discharge of 1.82 tons of ammonia nitrogen and 16.4 tons of chemical oxygen demand (COD) annually, which is within the permitted limits[128]. - The company has installed a low-nitrogen natural gas boiler with a capacity of 10 tons and 6 tons, which has been operational since October 2020, ensuring nitrogen oxide emissions are compliant with standards[128]. - The company has established an emergency response plan for environmental incidents, with a command center led by the general manager[137]. - The company has implemented measures to prevent environmental pollution incidents, ensuring the safety of the environment and public health[138]. Corporate Governance - The company has established a governance structure that ensures the protection of shareholder and creditor rights[152]. - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[114]. - The company has committed to distributing at least 10% of its distributable profits in cash dividends annually for the next three years, with potential increases if net profits continue to grow[159]. Related Party Transactions - The company reported a total of 632,000 RMB in related party transactions, accounting for 12.97% of similar transaction amounts[168]. - The approved transaction amount for related party transactions was 1,400,000 RMB, with no transactions exceeding this limit[168]. - The company has not provided any guarantees to related parties during the reporting period[182].

二○二二年六月十七日 | --- | --- | --- | --- | |--------------------------------|--------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------| | | | | | | 证券代码： | 002100 | 证券简称：天康生物 | | | 债券代码： | 128030 | 债券简称：天康转债 | 公告编号： 2022-044 | | | | 天康生物股份有限公司 | | | | | 关于参加 2022 | 年新疆辖区投资者 | | | | 网上集体接待日暨上市公司业绩说明会活动的公告 | | | | | | 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 | | 记载、误导性陈述或者重大遗漏。 | | | | | | | | 为便于广大投资者更深入全面地了解公司情况、 ...

Financial Performance - The company's revenue for Q1 2022 was ¥3,391,929,405.09, representing a 1.58% increase compared to ¥3,339,230,680.67 in the same period last year[4] - The net profit attributable to shareholders was -¥69,605,796.25, a decrease of 123.12% from ¥301,009,811.74 in the previous year[4] - The net cash flow from operating activities was -¥808,347,021.44, a decline of 238.17% compared to ¥585,028,585.93 in Q1 2021[4] - The company's total equity decreased from ¥7,783,303,372.25 to ¥7,603,798,910.94, representing a decrease of approximately 2.3%[23] - The net profit for the current period was a loss of CNY 108,566,710.19, compared to a profit of CNY 312,204,675.61 in the previous period, indicating a substantial decline[27] - The company reported a basic and diluted earnings per share of -0.05, down from 0.28 in the previous period[30] - The total comprehensive income for the current period was a loss of CNY 188,142,159.14, compared to a comprehensive income of CNY 312,204,675.61 in the previous period[30] Cash Flow - The company's cash and cash equivalents decreased from ¥3,424,083,819.49 at the beginning of the year to ¥2,322,436,762.83, representing a decline of approximately 32.3%[14] - Cash inflow from operating activities totaled CNY 3,162,894,211.54, a decrease from CNY 3,524,356,259.57 in the previous period[31] - The net cash flow from operating activities was -$808,347,021.44, a decrease from $585,028,585.93 in the previous period[34] - Cash outflow from operating activities totaled $3,971,241,232.98, compared to $2,939,327,673.64 previously[34] - The ending cash and cash equivalents balance was $2,175,960,504.84, up from $1,732,129,657.41 at the beginning of the period[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥17,090,267,464.43, a decrease of 0.55% from ¥17,184,738,668.37 at the end of the previous year[4] - Accounts receivable increased significantly from ¥323,390,791.30 to ¥562,498,770.36, marking an increase of about 74%[17] - Inventory rose from ¥5,231,785,064.81 to ¥5,811,482,596.45, indicating an increase of approximately 11%[17] - Current liabilities decreased from ¥6,956,371,740.34 to ¥6,720,954,878.66, a reduction of about 3.4%[20] - Long-term borrowings increased from ¥1,964,000,000.00 to ¥2,254,000,000.00, reflecting a growth of approximately 14.7%[20] - The total liabilities increased from ¥9,401,435,296.12 to ¥9,486,468,553.49, an increase of about 0.9%[20] Expenses - Research and development expenses increased by 44.43% to ¥38,129,010.71 from ¥26,399,254.36 in the same period last year[6] - Total operating costs increased significantly to CNY 3,497,856,389.13 from CNY 2,991,259,996.71, marking an increase of about 17%[24] - The company experienced a significant increase in sales expenses, which rose to CNY 102,896,660.62 from CNY 87,342,342.14, an increase of approximately 17.5%[24] - The company reported a decrease in tax expenses to CNY 10,771,066.79 from CNY 13,843,938.13, a reduction of about 22.5%[27] Investment and Financing - The company received government subsidies amounting to ¥7,234,780.66, an increase of 25.47% from ¥5,766,068.36 in the same period last year[6] - The company’s investment income decreased by 54.58% to ¥8,040,381.48 from ¥17,701,587.34 in the previous year[6] - Cash inflow from financing activities was $1,021,500,000.00, an increase from $985,000,000.00 in the prior period[34] - Cash outflow from financing activities amounted to $1,144,078,555.00, down from $1,568,151,019.49 previously[34] - The company incurred tax payments of $21,987,065.28, a decrease from $41,290,626.14 in the prior period[34] - The company reported cash outflow for fixed assets and intangible assets acquisition at $127,769,859.28, down from $198,136,050.00[34]

Financial Performance - In 2021, TianKang Bio experienced significant losses in its pig farming business due to a sharp decline in domestic pig sales prices, marking the company's first loss in over 20 years[5]. - The company's operating revenue for 2021 was ¥15,744,337,617.02, representing a 31.35% increase compared to ¥11,986,808,944.23 in 2020[34]. - The net profit attributable to shareholders for 2021 was -¥685,964,477.34, a decrease of 139.87% from ¥1,720,414,461.95 in 2020[34]. - The net cash flow from operating activities improved significantly to ¥1,532,960,475.93, compared to -¥600,857,389.57 in 2020, marking a 355.13% increase[34]. - The total assets at the end of 2021 were ¥17,184,738,668.37, which is a 9.25% increase from ¥15,729,293,585.91 at the end of 2020[34]. - The company reported a basic earnings per share of -¥0.62 for 2021, down 138.51% from ¥1.61 in 2020[34]. - The weighted average return on equity for 2021 was -11.75%, a decline of 43.61% from 31.86% in 2020[34]. - The company reported a net profit attributable to shareholders of CNY -68,596.45 million, a decline of 139.87% compared to the previous year[68]. Business Strategy and Operations - The company aims to stabilize its pig farming scale at 5 million heads, focusing on healthy and high-quality development[5]. - The overall strategy for 2022 includes maintaining a complete industry chain and focusing on high-quality development amidst the challenges of the "pig cycle"[5]. - The company plans to explore futures hedging with a target amount of 1 billion RMB in 2022 to mitigate risks associated with falling pig prices[6]. - The company will implement a cost reduction strategy by establishing a cost big data analysis and early warning platform to identify and control cost points[6]. - The management emphasizes the importance of learning from the experiences of 2021 to navigate future opportunities and challenges[7]. - The company aims to achieve a feed production and sales volume of 3 million tons, with a target of 220,000 pigs slaughtered and 1.989 billion yuan in total revenue for 2022[177]. - The company will focus on a full-cost leadership strategy in its feed business, ensuring efficiency across procurement, production, logistics, and human resources[178]. Research and Development - TianKang Bio will enhance research and development efforts in feed and breeding technology to further reduce costs[6]. - The company has committed to not distributing cash dividends or bonus shares for the year[12]. - The company has developed a vaccine for porcine reproductive and respiratory syndrome (PRRS) that requires only a single injection, reducing labor and stress on pigs, which is expected to positively impact performance[1]. - The company has obtained new veterinary drug registration certificates for multiple vaccines, including those for porcine pleuropneumonia and foot-and-mouth disease, enhancing its product portfolio[1]. - The company aims to enhance its market competitiveness by diversifying its vaccine product line with the successful development of new vaccines[96]. - The company achieved a research and development investment of ¥142,889,664.78 in 2021, representing a 37.41% increase from ¥103,986,145.98 in 2020[108]. - The proportion of R&D investment to operating revenue increased to 0.91% in 2021 from 0.87% in 2020, showing a slight growth of 0.04%[108]. Market and Industry Trends - In 2021, China's pork production reached 52.96 million tons, an increase of 28.8% year-on-year, with a total of 671.28 million pigs slaughtered, up 27.4% from the previous year[171]. - By the end of 2021, the national pig stock was 449.22 million heads, and the breeding sow stock was 43.29 million heads, representing growth of 10.5% and 4.0% respectively compared to the end of 2020[171]. - The agricultural policy aims to stabilize pork production capacity at around 55 million tons and maintain a self-sufficiency rate of approximately 95% for pork[173]. - The company recognizes the increasing market concentration in the feed industry and aims to leverage its core competencies to thrive amid challenges[170]. Risk Management and Compliance - The company has established a robust biosecurity management system for pig farming to mitigate the risks associated with African swine fever, which remains a significant threat since the first case was reported in August 2018[185]. - The company has strengthened its internal control systems and governance structures in compliance with relevant laws and regulations, ensuring operational transparency[194]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards[197]. - The company has maintained fair and reasonable related-party transactions with its controlling shareholder, ensuring independence in operations and decision-making[196]. Investment and Financing - The company raised 2.066 billion RMB through a private placement at the end of 2021 and plans to apply for a bank financing limit of 9.61 billion RMB in 2022 to maintain stable cash flow[6]. - The total investment amount for the reporting period was ¥1,790,315,527.80, representing a 91.43% increase from the previous year's investment of ¥935,224,113.03[118]. - The company has established a professional futures team to monitor market price trends and control futures positions[128]. - The company has completed the replacement of 38,797.86 million yuan of self-raised funds with raised funds for investment projects[144].